Foghorn Therapeutics Inc.

NasdaqGM:FHTX Voorraadrapport

Marktkapitalisatie: US$435.9m

Foghorn Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De winst van Foghorn Therapeutics zal naar verwachting dalen met 2.8% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 32.1% per jaar. De winst per aandeel zal naar verwachting groeien met 5.9% per jaar.

Belangrijke informatie

-2.8%

Groei van de winst

5.9%

Groei van de winst per aandeel

Biotechs winstgroei28.3%
Inkomstengroei32.1%
Toekomstig rendement op eigen vermogenn/a
Dekking van analisten

Good

Laatst bijgewerkt05 Nov 2024

Recente toekomstige groei-updates

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 07
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

May 09
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Recent updates

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Nov 07
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Oct 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) 28% Share Price Plunge Could Signal Some Risk

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Sep 01
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Shares Climb 35% But Its Business Is Yet to Catch Up

Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Jul 17
Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 27% But Growth Is Lacking

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

May 09
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target

Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Apr 12
Companies Like Foghorn Therapeutics (NASDAQ:FHTX) Are In A Position To Invest In Growth

Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Feb 22
Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Share Price Boosted 71% But Its Business Prospects Need A Lift Too

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Dec 13
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Fly 33% But Investors Aren't Buying For Growth

Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Nov 07
Need To Know: Analysts Are Much More Bullish On Foghorn Therapeutics Inc. (NASDAQ:FHTX) Revenues

Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Jun 14
Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans

Foghorn Therapeutics: Selling For Less Than Cash Value

Oct 10

Foghorn stock slumps 18% as FDA places full clinical hold on blood cancer trial of FHD-286

Aug 23

Foghorn Therapeutics GAAP EPS of -$0.66 misses by $0.07, revenue of $4.49M

Aug 09

Foghorn: Big Pharma Interest, Resolvable Clinical Hold Equals Opportunity

Jun 02

We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Apr 13
We're Hopeful That Foghorn Therapeutics (NASDAQ:FHTX) Will Use Its Cash Wisely

Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Feb 27
Are Insiders Buying Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock?

Winst- en omzetgroeiprognoses

NasdaqGM:FHTX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202638-110-110-846
12/31/202534-91-89-908
12/31/202427-91-95-1006
9/30/202426-91-104-103N/A
6/30/202435-86-110-110N/A
3/31/202434-93-117-116N/A
12/31/202334-98-119-118N/A
9/30/202333-103-121-119N/A
6/30/202322-115-114-112N/A
3/31/202321-112-111-109N/A
12/31/202219-109192194N/A
9/30/202216-109233234N/A
6/30/20229-109233234N/A
3/31/20225-105243244N/A
12/31/20211-101-54-50N/A
9/30/20211-93-84-73N/A
6/30/20211-85-65-50N/A
3/31/20211-78-61-44N/A
12/31/20200-69-47-31N/A
9/30/20200-63-43-34N/A
6/30/2020N/A-58-52-49N/A
3/31/2020N/A-54-48-47N/A
12/31/2019N/A-51-47-46N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat FHTX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat FHTX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat FHTX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van FHTX ( 32.1% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van FHTX ( 32.1% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van FHTX naar verwachting over 3 jaar hoog zal zijn


Ontdek groeibedrijven